Cleveland Clinic Florida Hosts First Annual CME Course

Hit the highlights from the 2017 San Antonio Breast Cancer Symposium™ with a one-day official Best of SABCS review sponsored by Cleveland Clinic Florida and endorsed by the Florida Society of Clinical Oncology.

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

SABCS is the premier conference in the U.S. and the world designed to provide the latest on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease to health professionals, physicians and researchers.

Who should attend

This review course is directed primarily towards academic physicians and researchers involved in breast cancer in medical, surgical, gynecologic and radiation oncology, as well as other appropriate health care professionals.

Topics include:

Advances in hormonal therapy and mechanisms of resistance
Advances in HER2+ breast cancer
Imaging/local therapies/surgery update
New therapeutic approaches for triple negative/BRCA-related breast cancer
Survivorship care
Systemic therapies and molecular prediction models

Zeina Nahleh, MD, FACP, Director of the Maroone Cancer Center and Chair of the Department of Hematology/Oncology at Cleveland Clinic Florida, will lead the course.

Faculty include Cleveland Clinic experts Jame Abraham, MD, George Thomas Budd, MD, and Margaret Thompson, MD, as well as guest faculty Helen Chew, MD, of University of California Davis Cancer Center and Debu Tripathy, MD, of University of Texas MD Anderson Cancer Center.

This course will enable you to report the most current information on breast cancer research presented at SABCS in December, discuss the information with colleagues and key opinion leaders, and integrate into clinical practice various evidence-based advances to management in imaging, surgery and local and systemic therapies surrounding HER2+, BRCA-related breast cancer, hormonal therapy, molecular predictions models and survivorship.

For a full agenda and to register, visit the program site.

This activity has been approved for AMA PRA Category 1 credit™.